Poor prognosis of colorectal cancer in patients over 80 years old is associated with down-regulation of tumor suppressor genes

Journal of Clinical Gastroenterology

Volumn 37, Issue 1, 2003, Pages 48-54

  Nagaoka, Sakae ^a,b   Shiraishi, Junichi ^a   Utsuyama, Masanori ^a   Seki, Sachiko ^a   Takemura, Tamiko ^c   Kitagawa, Masanobu ^a   Sawabe, Motoji ^d   Takubo, Kaiyo ^e   Hirokawa, Katsuiku ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Department of Surgery ^*  (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d Tokyo Metropolitan Institute of Gerontology   (Japan)

^e TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Aging; Colorectal cancer; MRNA; P27; P53

Indexed keywords

PROTEIN P27; PROTEIN P53;

AGED; AGING; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; FEMALE; FROZEN SECTION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR DOWN REGULATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENES, TUMOR SUPPRESSOR; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0038613647     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200307000-00013     Document Type: Article

References (43)

1. Health and welfare statistics association. The Ministry of Health, Labor and Welfare of Japan. Journal of Health and Welfare Statistics. 2001;48:72-73.
2. Jessup JM, McGinnis LS, Steele GD Jr, et al. The National Cancer Data Base. Report on colon cancer. Cancer. 1996;78:918-926.
3. Kemppainen M, Raiha I, Rajala T, et al. Characteristics of colorectal cancer in elderly patients. Gerontology. 1993;39:222-227.
4. Mulcahy HE, Patchett SE, Daly L, et al. Prognosis of elderly patients with large bowel cancer. Br J Surg. 1994;81:736-738.
5. Arveux I, Boutron MC, El Mrini T, et al. Colon cancer in the elderly: evidence for major improvements in health care and survival. Br J Cancer. 1997;76:963-967.
6. McKenna RJ Sr. Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up. Cancer. 1994;74:2107-2117.
7. Arai T, Takubo K, Sawabe M, et al. Pathologic characteristics of colorectal cancer in the elderly: a retrospective study of 947 surgical cases. J Clin Gastroenterol. 2000;31:67-72.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
9. Lynch HT, Lynch JF. Genetics of colonic cancer. Digestion. 1998;59:481-492.
10. Olschwang S, Hamelin R, Laurent-Puig P, et al. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A. 1997;94:12122-12127.
11. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
12. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912-915.
13. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
14. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
15. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169-1174.
16. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85:721-732.
17. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707-720.
18. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
19. Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann. 1980;71:260-264.
20. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-234.
21. Palmqvist R, Stenling R, Oberg A, et al. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol. 1999;188:18-23.
22. Liu DF, Ferguson K, Cooper GS, et al. p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer. J Clin Lab Anal. 1999;13:291-295.
23. Sgambato A, Ratto C, Faraglia B, et al. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinogenesis. 1999;26:172-179.
24. Hirano K, Minamoto T. Altered expression of p53 and p27 proteins, alone or combined, as a predictor of metastatic potential in early invasive carcinoma of colon and rectum - a comparative clinicopathologic and molecular analysis. Cancer Detect Prev. 2000;24:343-355.
25. Zhang H, Sun XF. Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol. 2001;19:49-52.
26. Matsushita K, Kobayashi S, Kato M, et al. Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer. 1996;69:259-264.
27. Girlando S, Slomp P, Caffo O, et al. p21 expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. Virchows Arch. 1999;435:559-565.
28. Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000;436:224-228.
29. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998;58:4823-4826.
30. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000;6:4064-4068.
31. Tsujii M. COX-2 inhibitor and colon cancer. Jpn J Cancer Chemother. 2001;28:1799-1805.
32. Yamauchi T, Watanabe M, Kubota T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum. 2002;45:98-103.
33. Japanese Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 6th ed. Tokyo: Kanehara & Co., Ltd.; 1998.
34. Ikeda Y, Koyanagi N, Mori M, et al. Increased incidence of proximal colon cancer in the elderly. J Clin Gastroenterol. 1996;23:105-108.
35. Butcher D, Hassanein K, Dudgeon M, et al. Female gender is a major determinant of changing subsite distribution of colorectal cancer with age. Cancer. 1985;56:714-716.
36. Jass JR. Subsite distribution and incidence of colorectal cancer in New Zealand, 1974-1983. Dis Colon Rectum. 1991;34:56-59.
37. Vobecky J, Leduc C, Devroede G. Sex differences in the changing anatomic distribution of colorectal carcinoma. Cancer. 1984;54:3065-3069.
38. Alley PG, McNee RK. Age and sex differences in right colon cancer. Dis Colon Rectum. 1986;29:227-229.
39. Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem - how do we apply what we know? Cancer. 1994;74:1995-2003.
40. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222-225.
41. Lanza G Jr, Maestri I, Dubini A, et al. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol. 1996;105:604-612.
42. Tomoda H, Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J Surg Oncol. 1995;58:125-128.
43. Tanaka K, Nagaoka S, Takemura T, et al. Incidence of apoptosis increases with age in colorectal cancer. Exp Gerontol. 2002;37:1469-1479.